



Dr. Hertz C. Gerstein is an Endocrinologist and Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Institute Chair in Diabetes Research. He is also Director of the Division of Endocrinology & Metabolism, Director of the Diabetes Care and Research Program and Deputy Director of the Population Health Research Institute. He has received several honors including the Canadian Diabetes Association's Young Scientist Award (1999), Frederick G. Banting award (1999), and Charles H. Best award (2007).

Dr. Gerstein has led the application of large simple outcome trials to people with diabetes globally, and developed the concept of dysglycemia as an important risk factor for many of the serious health outcomes that afflict people with an elevated glucose level regardless of diabetes status. He currently leads clinical trials and epidemiologic studies related to: a) the prevention and therapy of diabetes and its many consequences, and b) the role of dysglycemia and relative insulin insufficiency on the development of diabetes, cardiovascular disease, cognitive impairment and other chronic conditions. His research spans over 50 countries, and has been funded by the Canadian Institutes of Health Research, the National Institutes of Health, the Heart and Stroke Foundation, the Canadian Diabetes Association and Industry. Key studies in which he has played or continues to play a major leadership role include HOPE, MICRO HOPE, ACCORD, DREAM, EpiDREAM, ORIGIN, TIDE, ACE, CANVAS, ELIXA and REWIND. In addition to his research, he was the founding director of Diabetes Hamilton – a novel publicly available program that facilitated the ability of people with diabetes to best manage their disease.